Are Fibrocystic Changes Innocent? Importance of HER-2 in Fibrocystic Changes of Breast and Correlation Breast Cancer Risk

Objective: Fibrocystic change refers to nonproliferative lesion. Determining whether this lesion is a risk factor for developing breast cancer has been one of the most important issues. In order to determine this risk, we used HER-2 by immunohistochemistry in this study. Material and Method: 163 mastectomy materials which had tumor diagnosis between 1995 and 2016 in our clinic and had findings of fibrocystic changes in non-tumor areas, and 151 excisional breast biopsy materials which had diagnosis of fibrocystic change but had not malignant mass were included into the study. The tissues containing fibrocystic changes in both groups were stained with HER-2 by immunohistochemical methods. Results: It was found that HER-2 staining was more frequent in FCC areas with in mastectomy cases due to tumor (χ2 = 37,079; p =,000). Conclusions: We found out that HER 2 staining was significantly more positive in fibrocystic change cases with in mastectomy cases due to tumor than non-malignant cases and that the risk of malignancy was higher in HER-2 positive cases. We believe that HER-2 staining for breast biopsies will be helpful for determining malignancy potential in benign lesions of breast.

Fibrokistik Değişiklikler Masum mudur? Memenin Fibrokistik Değişikliklerinde HER-2’nin Önemi ve Meme Kanseri ile İlişkisi

Amaç: Fibrokistik değişiklik nonproliferatif bir lezyondur. Bu lezyonun meme kanseri gelişiminde bir risk faktörü olup olmadığını belirlemek en önemli konularından biri olmuştur. Bu riski belirlemek için, bu çalışmada immünohistokimyasal olarak HER-2 kullanılmıştır. Gereç ve Yöntem: Kliniğimizde 1995-2016 yılları arasında tümör tanısı alan ve tümör olmayan bölgelerde fibrokistik değişiklikleri olan 163 mastek-tomi materyali ile fibrokistik değişiklik tanısı konan ancak malign kitlesi olmayan 151 eksizyonel meme biyopsisi materyali çalışmaya alındı. Her iki gruptaki fibrokistik değişiklikleri içeren dokular HER-2 ile immünohistokimyasal yöntemlerle boyandı. Bulgular: Tümör nedeniyle mastektomi yapılan olguların tümör dışı fibrokistik alanlarında HER-2 boyanmasının anlamlı derecede yüksek olduğu saptandı (χ2 = 37,079; p=,000). Sonuç: HER -2 boyamasının tümör nedeniyle mastektomi yapılan olgularda tümör dışı alanlarda fibrokistik değişim gösteren dokularında malign olmayan olgulara kıyasla anlamlı olarak daha pozitif olduğunu ve HER-2 pozitif olgularda malignite riskinin daha yüksek olduğunu tespit ettik. Meme biyopsileri için HER-2 boyanmasının meme benign lezyonlarında malignite potansiyelinin belirlenmesine yardımcı olacağına inanıyoruz.

___

Bartow SA, Pathak DR, Black WC, Key CR, Teaf SR. Prevalence of benign, atypical, and malignant breast lesions in populations at different risk for breast cancer. A forensic au-topsy study. Cancer 1987; 60: 2751- 60.

Fiorica JV. Fibrocystic changes. Obstet Gynecol Clin North Am 1994; 21: 445-52.

Hutter RVP. Consensus meeting. Is fibrocystic disease of the breast precancerous. Arch Pathol 1986; 110: 171-3.

Hockenberger SJ. Fibrocystic breast disease: every woman is at risk. Plast Surg Nurs 1993; 13: 37-40.

Vorherr H. Fibrocystic breast disease: pat-hophysiology, pathomorphology, clinical pictu-re, and management. Am J Obstet Gynecol 1986; 154: 161-79.

Wellings SR, Alpers CE. Apocrine cystic me-taplasia: subgross pathology and prevalence in cancer-associated versus random autopsy bre-asts. Hum Pathol 1987; 18: 381-6.

Jacobs TW, Gown AM, Yaziji H, Barnes MJ, Schnitt SJ. HER-2/neu protein expression in breast cancer evaluated by immunohistoche-mistry. A study of interlaboratory agreement. Am J Clin Pathol 2000; 113: 251-8.

Couturier J, Vincent-Salomon A, Nicolas A et al. Strong correlation between results of fluores-cent in situ hybridization and immunohistoche-mistry for the assessment of the ERBB2 (HER-2/neu) gene status in breast carcinoma. Mod Pathol 2000; 13: 1238-43.

Ridolfi RL, Jamehdor MR, Arber JM. HER-2/neu testing in breast carcinoma: a combined immunohistochemical and fluorescence in situ hybridization approach. Mod Pathol 2000; 13: 866-73.

Hartmann LC, Sellers TA, Frost MH et al. Be-nign breast disease and the risk of breast cancer. N Engl J Med 2005; 353: 229–37.

Wolff AC, Hammond ME, Schwartz JN et al. American Society of Clinical Onco-logy; College of American Pathologists. Ameri-can Society of Clinical Oncology/College of American Pathologists Guideline recommenda-tions for human epidermal growth factor recep-tor 2 testing in breast cancer. Arch Pathol Lab Med 2007; 25: 118-45.

Hutter RVP. Consensus meeting: is“fibrocystic disease” of the breast precancerous? Arch Pat-hol Lab Med 1986; 110: 171–83.

Fitzgibbons PL, Henson DE, Hutter RVP. Be-nign breast changes and the risk for subsequent breast cancer. Arch Pathol Lab Med 1998; 122: 1053–5.

Gail MH, Brinton LA, Byar DP et al. Projecting individualized probabilities of developing breast cancer for white females who are being exami-ned annually. J Natl Cancer Inst 1989; 81: 1879-86.

Wang J, Costantino JP, Tan-Chiu E, Wickerham DL, Paik S, Wolmark N. Lower category benign breast disease and the risk of invasive breast cancer. J Natl Cancer Inst 2004; 96: 616-20.

Carter CL, Corle DK, Micozzi MS, Schatzkin A, Taylor PR. A prospective study of the deve-lopment of breast cancer in 16692 women with benign breast disease. Am J Epidemiol 1988; 128: 467-77.

London SJ, Connolly JL, Schnitt SJ, Colditz GA. A prospective study of benign breast disea-se and the risk of breast cancer. JAMA 1992; 267: 941-4.

Schnitt SJ. Benign breast disease and breast cancer risk: potential role for antiestrogens. Clin Cancer Res 2001; 7: 4411-22.

Melton LJ 3rd. The threat to medical records research. N Engl J Med 1997; 337: 1466-70.

Page DL, Dupont WD, Rogers LW, Rados MS. Atypical hyperplastic lesions of the female bre-ast: a long-term follow-up study. Cancer 1985; 55: 2698-08.

Youngson BJ, Mulligan AM. Fibrocystic Change and Columnar Cell Lesions. Breast Pathology. In: Goldblum; editor. Philadelphia; Elsevier; 2011; pp 149-58.

Moinfar F. Fibrocystic Change. Essentials of Diagnostic Breast Pathology In: Moinfar F; edi-tor. Berlin; Springer; 2007; pp 16-17.

Jones BM, Bradbeer JW. The presentation and progress of macroscopic breast cysts. Br J Surg 1980; 67: 669–71. 24. Ciatto S, Biggeri A, Del Turco MR, Bartoli D, Iossa A. Risk of breast cancer subsequent to proven gross cystic disease. Eur J Cancer 1990; 26: 555–7.

Bundred NJ, West RR, Dowd JO, Mansel RE, Huges LE. Is there an increased risk of breast cancer in women who have had a breast cyst as-pirated? Br J Cancer 1991; 64: 953–5.

Lundin C, Mertens F. Cytogenetics of benign breast lesions. Breast Cancer Res Treat 1998; 51: 1–15.

Peto R, Boreham J, Clarke M, Davies C, Beral V. UK and USA breast cancer deaths down 25% in year 2000 at ages 20–69 years. Lancet 2000; 355:1822.

Etzioni R, Urban N, Ramsey S, McIntosh M, Schwartz S, Reid B. The case for early detec-tion. Nat Rev Cancer 2003; 3: 243 –52.

Braakhuis BJ, Tabor MP, Kummer JA, Leemans CR, Brakenhoff RH. A genetic explanation of Slaughter’s concept of field cancerization: Evi-dence and clinical implications. Cancer Res 2003; 63: 1727 –30.

Tabor MP, Brakenhoff RH, Ruijter-Schippers HJ, Kummer JA, Leemans CR, Braakhuis BJ. Genetically altered fields as origin of locally re-current head and neck cancer: A retrospective study. Clin Cancer Res 2004; 10: 3607–13.

Viola M, van Houten M, Leemans CR et al. Molecular diagnosis of surgical margins and lo-cal recurrence in head and neck cancer patients: A prospective study. Clin Cancer Res 2004; 10: 3614–20.

Botti C, Pescatore B, Mottolese M et al. Inci-dence of chromosomes 1 and 17 aneusomy in breast cancer and adjacent tissue: An interphase cytogenetic study. J Am Coll Surg 2000; 190: 1–10.

Rohan TE, Hardwick W, Miller AB, Kandel RA. Immunohistochemical detection of c-erbb-2 and p53 in benign breast disease and breast can-cer risk. Nat Cancer Inst 1998; 90: 1262-9.

Gusterson BA, Machin LG, Gullick WJ et al. CerbB-2 expression in benign and malignant breast disease. Br J Cancer 1988; 58: 453-7.

Foote FW, Stewart FW. Comparative studies of cancerous versus non-cancerous breasts. Basic morphologic characteristics. Ann Surg 1945; 121: 6-53.

Wellings SR, Alpers CE. Apocrine cystic me-taplasia: subgross pathology and prevalence in cancer-associated versus random autopsy bre-asts. Hum Pathol 1987; 18: 381-6.
Fırat Tıp Dergisi-Cover
  • ISSN: 1300-9818
  • Başlangıç: 2015
  • Yayıncı: Fırat Üniversitesi Tıp Fakültesi
Sayıdaki Diğer Makaleler

Elazığ ve Çevresinde Avcılarda Tularemi Görülme Sıklığının Mikroaglütinasyon Yöntemiyle Araştırılması

Zülfü BAYAR, Mehmet AKSU, MUSTAFA YILMAZ

Dactylorhiza osmanica’nın Topraküstü Kısımlarında Antioksidan, Antimikrobiyal ve Tirozinaz İnhibitör Aktivitelerinin Araştırılması

REZZAN ALİYAZICIOĞLU, Nuriye KORKMAZ, Şeyda AKKAYA, SILA ÖZLEM ŞENER, UFUK ÖZGEN, ŞENGÜL ALPAY KARAOĞLU

Alkaptonuric Ochronosis; Hip Arthropathy - A Rare Case Treated with Total Hip Replacement

Mehmet YETİŞ, Zafer ÜNVEREN, ERDAL UZUN, Mustafa ÖZÇAMDALLI, Turan Bilge KIZKAPAN, Abdulhamit MİSİR

A Polymorphous Low-Grade Adenocarcinoma of the Tong

Aykut BOZAN, Ayşe POLAT, Denizhan DİZDAR, Hayrettin Cengiz ALPAY

Are Fibrocystic Changes Innocent? Importance of HER-2 in Fibrocystic Changes of Breast and Correlation Breast Cancer Risk

ÖZGEN ARSLAN SOLMAZ

Fibrokistik Değişiklikler Masum mudur? Memenin Fibrokistik Değişikliklerinde HER-2’nin Önemi ve Meme Kanseri ile İlişkisi

Özgen ARSLAN SOLMAZ

Süt Çocukluğu Döneminde Akrep Sokması: Olgu Sunumu

Mehmet Yusuf SARI, MEHMET KILIÇ, Mustafa AYDIN, ERDAL TAŞKIN

Üniversite Öğrencilerinin Nargile İçme Konusundaki Bilgi, Tutum ve Davranışları

Ayhan AKTAŞ, SEYHAN HIDIROĞLU, MELDA KARAVUŞ

Edinsel Anatomik Bozukluğa Bağlı Çekal Volvulus Olgusu

Talha SARİGÖZ, Ramazan AZAR, Yusuf SEVİM, İnanç Şamil SARICI, TAMER ERTAN, ÖMER TOPUZ

Mide Kanseri Tedavisinde Açık ve Laparoskopik Distal Subtotal Gastrektominin Kısa Dönem Onkolojik Sonuçları

İLHAN ECE, Fahrettin ACAR, HÜSEYİN YILMAZ, BAYRAM ÇOLAK, SERDAR YORMAZ, MUSTAFA ŞAHİN